A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates-Reference-Cited by-同舟云学术

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

Published:2018-02-20 Issue:2 Volume:13 Page:e0192312
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Callendret Benoit,Vellinga Jort,Wunderlich Kerstin,Rodriguez Ariane,Steigerwald Robin,Dirmeier Ulrike,Cheminay Cedric,Volkmann Ariane,Brasel Trevor,Carrion Ricardo,Giavedoni Luis D.,Patterson Jean L.,Mire Chad E.,Geisbert Thomas W.,Hooper Jay W.,Weijtens Mo,Hartkoorn-Pasma Jutta,Custers Jerome,Grazia Pau Maria,Schuitemaker Hanneke,Zahn Roland^ORCID

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference61 articles.

1. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis;M Goeijenbier;Neth J Med,2014

2. World Health Organization. Ebola virus disease. Fact sheet [updated June 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs103/en/

3. Mapping the zoonotic niche of Ebola virus disease in Africa;DM Pigott;eLife,2014

4. Mapping the zoonotic niche of Marburg virus disease in Africa;DM Pigott;Trans R Soc Trop Med Hyg,2015

5. International Committee on Taxonomy of Viruses. Virus Taxonomy: 2016 Release. Available from: https://talk.ictvonline.org/taxonomy/

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases;Nature Communications;2024-09-03

2. Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial;The Journal of Infectious Diseases;2024-07-16

3. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial;The Lancet Infectious Diseases;2024-07

4. Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines;Antiviral Research;2024-05

5. Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus;Frontiers in Immunology;2024-04-03